Depemokimab: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Depemokimab. Educational only — not medical advice.

Labeled uses

EXDENSUR is indicated for the add‑on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. Limitations of Use EXDENSUR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions (5.2 )] .

Source: FDA labeling via NIH DailyMed (set 30332b20…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.